What Erasca, Inc. does.

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally each year. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. Our focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) targeting RAS directly; and (3) targeting escape routes that emerge in response to treatment. Our pipeline enables us to pursue a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs.

Revenue and profit, by fiscal year.

More on ERAS.

• Erasca, Inc. summary
• Erasca, Inc. financial statements
• Erasca, Inc. key metrics
• Erasca, Inc. health scores and style box
• Erasca, Inc. earnings
• Erasca, Inc. dividends
• Erasca, Inc. valuation
• Erasca, Inc. ownership and insiders
• Erasca, Inc. peers

Figures from Erasca, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.